SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk
Prof Silvio E Inzucchi, Yale Diabetes Center, New Haven, CT, USA
10' education - Sep. 29, 2015Video navigation menu
T2DM pathogenesis 00:01
SGLT2 Inhibitors: How do they work? 06:53
Potential pathways to CV benefits of SGLT2-inhibitors based on clinical and mechanistic studies 11:01
SGLT2 inhibitors and the kidney 16:20
SGLT2 Inhibitors: Risks & Benefits 19:08
2015 ADA-EASD Position Statement on Management of Hyperglycemia in T2DM 22:40
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.